Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial

Completed · Phase 1

Conditions studied: Telangiectasia

In brief

This research is being done to look at the effects of an experimental drug, ranibizumab, for the treatment of a condition called "idiopathic parafoveal telangiectasia" or IPT. IPT is caused by swelling in the retina (the light sensitive tissue in the back of the eye) due to leaky blood vessels in this area. Swelling in the retina can lead to blurry vision.

Key facts

Study ID

NCT00378196

Run by

Johns Hopkins University

People needed

10

Starts

2006-09-01

Expected to finish

2008-12-01

Last updated by the study team

2012-11-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects will be eligible if the following criteria are met:
• Ability to provide written informed consent and comply with study assessments for the full duration of the study.
• Age > 18 years
• Diagnosis of bilateral IPT with macular edema documented on OCT and no evidence of choroidal neovascularization.
• Best corrected visual acuity of better or equal to 20/200 in both eye

You may not qualify if…

• Subjects who meet any of the following criteria will be excluded from this study:
• Known hypersensitivity to humanized monoclonal antibodies
• History (within past 6 months) or evidence of severe cardiac disease (apparent in electrocardiogram abnormalities, clinical history of unstable angina, acute coronary syndrome, myocardial infarction, revascularization procedure within 6 months prior to baseline, atrial or ventricular tachyarrhythmias requiring ongoing treatment).
• History of stroke within 6 months of study entry.
• Current acute ocular or periocular infection.
• Any major surgical procedure within one month of study entry.
• Known serious allergies to fluorescein dye.
• Previous participation in a clinical trial (for either eye) involving anti-angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, Protein Kinase C inhibitors, etc) within last 6 months.
• Previous intravitreal drug delivery (e.g., intravitreal corticosteroid injection or device implantation) in the study eye within the last 6 months.
• History of subfoveal laser treatment in the study eye.
• History of other visually-limiting conditions such as optic neuropathy, amblyopia, choroidal neovascularization due to causes other than IPT in the study eye.
• Ocular inflammation (including trace or above) in the study eye.
• Inability to comply with study or follow up procedures.

Where it is running

• The Wilmer Eye Institute at Johns Hopkins — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.